Clinical trials: Light Chain (AL) Amyloidosis
Light Chain (AL) Amyloidosis
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis
A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in Mayo Stage IV patients with AL amyloidosis.
- Trial name
- AFFIRM-AL (NCT04973137)
- Testing
- Birtamimab, Standard of Care Chemotherapy
- Where
- 110 sites in United States, Australia and 21 more
- Volunteers
- 208 people
- Sponsor
- Prothena Biosciences Ltd.
AL Amyloidosis
A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
This is a phase 1/2 open label study of melphalan flufenamide (melflufen) in combination with dexamethasone for participants with Al amyloidosis following at least one prior line of therapy.
- Trial name
- NCT04115956
- Testing
- Melphalan-Flufenamide (Melflufen), Dexamethasone
- Where
- 9 sites in United States, Czechia and 7 more
- Volunteers
- 6 people
- Sponsor
- Oncopeptides AB
Amyloidosis
Bortezomib for Immunoglobulin Light Chain(AL) Amyloidosis
Although the use of bortezomib has reported efficacy in amyloid light chain (AL) amyloidosis, the role of bortezomib with dexamethasone (BD) in the first-line treatment of patients with AL amyloidosis should be determined.
- Trial name
- NCT02485613
- Testing
- bortezominb and dexamethasone
- Volunteers
- 72 people
- Sponsor
- Zhi-Hong Liu, M.D.
AL Amyloidosis
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
This phase I trial studies the side effects of isatuximab and to see how well it works in treating patients with high risk immunoglobulin light chain amyloidosis (AL amyloidosis).
- Trial name
- NCT04754945
- Testing
- Bortezomib, Cyclophosphamide, Dexamethasone
- Where
- 6 sites in United States
- Volunteers
- 11 people
- Sponsor
- Emory University
AL Amyloidosis (AL), t(11;14) Positive
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
The goal of this study is to evaluate the efficacy and safety of Sonrotoclax combined Regimen in patients with t(11;14) AL amyloidosis.
- Trial name
- NCT07335887
- Testing
- sonrotoclax, Daratumumab, Dexamethasone
- Where
- 3 sites in China
- Volunteers
- 39 people
- Sponsor
- Peking University People's Hospital
AL Amyloidosis
Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib
Standard treatment for AL Amyloidosis is high-dose melphalan and stem cell transplant. This study will compare the safety and effectiveness of standard treatment with high-dose melphalan and stem cell transplant, compared with…
- Trial name
- VelRand (NCT02489500)
- Testing
- Bortezomib, Melphalan, Neupogen
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Boston Medical Center
Amyloid Light-chain Amyloidosis
Teclistamab-Daratumumab in AL Amyloidosis
The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis. The study treatment is divided into cycles (C) and each cycle is 28 days (D).
- Trial name
- NCT07110844
- Testing
- Teclistamab, Daratumumab and Hyaluronidase-fihj
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Rajshekhar Chakraborty, MD
Primary Light Chain (AL) Amyloidosis
A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis
This Phase I study is designed to evaluate the safety and efficacy of FKC289 in subjects with relapsed/refractory primary light chain (AL) amyloidosis.The primary objectives are to assess the safety of FKC289 and to establish the…
- Trial name
- NCT07765524
- Testing
- FKC289 infusion
- Where
- 11 sites in China
- Volunteers
- 32 people
- Sponsor
- Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Relapsed/Refractory Systemic Light Chain Amyloidosis
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
This study is researching an experimental drug called linvoseltamab ("study drug"). This study is focused on patients who have AL amyloidosis that has returned or have failed other therapies and need to be treated again.
- Trial name
- LINKER-AL2 (NCT06292780)
- Testing
- Linvoseltamab
- Where
- 21 sites in United States, Greece and 4 more
- Volunteers
- 220 people
- Sponsor
- Regeneron Pharmaceuticals
Light Chain (AL) Amyloidosis, MRD
A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis
Before effective treatment, the prognosis of patients with AL amyloidosis is very poor, with a median survival of approximately 12 months.
- Trial name
- NCT07215494
- Testing
- First-Line Dara-BorCyD Treatment
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University First Hospital
Systemic Amyloidosis, ATTR Amyloidosis
Hungarian National Systemic Amyloidosis Registry
This registry is an observational, multicenter, retrospective and prospective, non-pharmacological study designed to collect and analyze data from patients with systemic amyloidosis treated in inpatient and outpatient cardiology…
- Conditions
- Systemic Amyloidosis, ATTR Amyloidosis, AL Amyloidosis, Amyloid Cardiomyopathy
- Trial name
- AMYREG (NCT07689331)
- Where
- 12 sites in Hungary
- Volunteers
- 300 people
- Sponsor
- Semmelweis University
Multiple Myeloma and Plasma Cell Neoplasm
Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis
The purpose of this study in patients needing treatment for AL amyloidosis is to see how well treatment with IV melphalan works and then, if some clonal plasma cells are still present about 2 to 3 months after melphalan…
- Trial name
- NCT00458822
- Testing
- bortezomib, dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Kidney Disease, Acute Myeloid Leukemia (AML)
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
The main purpose of this study is to examine the outcome of a combined bone marrow and kidney transplant from a partially matched related (haploidentical or "haplo") donor.
- Conditions
- Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML)
- Trial name
- BMT (NCT01758042)
- Testing
- Haploidentical Bone Marrow/Kidney
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
The primary purpose of this study is to identify the recommended phase 2 dose (RP2D[s]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at…
- Trial name
- NCT05652335
- Testing
- JNJ-79635322
- Where
- 29 sites in United States, Belgium and 5 more
- Volunteers
- 180 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma and Plasma Cell Neoplasm
4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: 4'-Iodo-4'-deoxydoxorubicin may improve organ dysfunction and ease symptoms caused by primary systemic amyloidosis. PURPOSE: Phase II trial to study the effectiveness of 4'-iodo-4'-deoxydoxorubicin in treating patients…
- Trial name
- NCT00003853
- Testing
- 4'-iodo-4'-deoxydoxorubicin
- Where
- 3 sites in United States, Italy
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Primary Systemic Amyloidosis
Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis
Iododoxorubicin may dissolve protein deposits and be an effective treatment for primary systemic amyloidosis. Phase I trial to determine the effectiveness of iododoxorubicin in treating patients who have primary systemic…
- Trial name
- NCT00030381
- Testing
- 4'-iodo-4'-deoxydoxorubicin, pharmacological study
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Amyloid, AL Amyloidosis
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
This study will test the hypothesis that in patients with previous daratumumab exposure, combination therapy of daratumumab, pomalidomide, and dexamethasone (DPd) will yield higher complete remission (CR) rates in…
- Conditions
- Amyloid, AL Amyloidosis, Refractory AL Amyloidosis
- Trial name
- NCT04270175
- Testing
- Daratumumab SC, Pomalidomide, Dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Weill Medical College of Cornell University
Light Chain Deposition Disease, Primary Systemic Amyloidosis
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
This phase I trial studies the side effects and best dose of pomalidomide and bortezomib when given together with dexamethasone in treating patients with amyloid light-chain amyloidosis or light chain deposition disease.
- Trial name
- NCT01728259
- Testing
- pomalidomide, bortezomib, dexamethasone
- Where
- 5 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Systemic Amyloidosis
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed or previous treated systemic light chain (AL) amyloidosis.
- Trial name
- NCT06342466
- Testing
- Bortezomib, Pomalidomide, Dexamethasone
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Jin Lu, MD
AL Amyloidosis
Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
The purpose of this study is to examine the tolerance, safety, pharmacokinetics, and possible clinical benefit of the good manufacturing practice (GMP)-grade amyloid fibril-reactive chimeric (Ch) IgG1 mAb 11-1F4 in patients with…
- Trial name
- NCT02245867
- Testing
- Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Alexion Pharmaceuticals, Inc.